Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands... Show more
Emerson Electric shares have traded in a relatively narrow, upward-sloping range in recent weeks. Over the 30-day window ending in late October 2026, the stock advanced about 6.3%, moving from a close near $155 in late September to roughly $165 by late October. The move was steady rather than sharp, with the stock trending higher through most of October after a period of consolidation near the $158–$163 level.
The modest gain is consistent with a stock that has not experienced a single dramatic catalyst but has instead benefited from a gradual improvement in investor sentiment tied to resilient order trends and stronger-than-expected quarterly results. Within the broader industrial and automation sector, Emerson continues to be positioned as a beneficiary of long-cycle capital spending on power infrastructure, semiconductor manufacturing, and energy transition projects.
Emerson Electric is a global automation technology and software company headquartered in St. Louis, Missouri. Over the past several years, the company has reshaped its portfolio into a pure-play automation leader by divesting its Climate Technologies business, acquiring National Instruments (Test & Measurement), and completing its full acquisition of AspenTech, a provider of asset optimization and industrial software.
The company operates through two primary segments. Intelligent Devices supplies measurement instrumentation, final control products such as valves and actuators, discrete automation, and safety and productivity equipment. Software & Control brings together Control Systems & Software (including the DeltaV and Ovation platforms), AspenTech, and Test & Measurement. This structure gives Emerson exposure to both process industries—oil and gas, chemicals, power, and life sciences—and discrete manufacturing such as semiconductors and electronics.
Investors follow EMR because of its installed base in critical facilities, high switching costs in process plants, and a growing recurring software component. Its primary competitors include Rockwell Automation, Honeywell, Siemens, ABB, and Schneider Electric.
Emerson's most consequential recent event was its fiscal third-quarter report, released in early August 2026. The company posted adjusted earnings of $1.71 per share, up 12.5% year over year and ahead of consensus, on revenue of $4.87 billion, a 7% increase. Underlying sales rose 6% and underlying orders advanced 7%, with management citing broad-based demand led by Software & Systems. Notably, the stock slipped in after-hours trading following the report despite the beat, reflecting some investor caution around software renewal dynamics and softness in Europe and China.
Growth was concentrated in the company's key verticals. Semiconductor sales rose about 53% and power sales climbed roughly 37%, supported by investment in generation capacity, grid modernization, and data-center demand. Test & Measurement sales increased 23%, while orders in the Ovation power-generation business rose 31%. Software annual contract value reached $1.68 billion, up 9% year over year.
On the back of these results, Emerson raised its fiscal 2026 outlook to approximately 5% net sales growth, about 3.5% underlying growth, and adjusted EPS of roughly $6.55, with free cash flow of about $3.6 billion. Management also signaled a shift in capital allocation toward returning cash to shareholders, planning around $1.2 billion in dividends and $1.0 billion in buybacks for the year. Separately, the company expanded its AI-related offerings, including enhancements to its NI Nigel AI capabilities, the AspenTech AVA AI platform, and the Inmation OT Data Fabric, and announced a partnership with L&T Technology Services.
Tickeron's Trending AI Robots page curates a selection of the platform's automated trading strategies. Tickeron offers hundreds of AI-driven trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, giving users a view into different approaches to pattern recognition and signal generation across the market. For investors and traders looking to complement their own research with algorithmic tools, the page offers a practical starting point for exploring how automated systems interpret price action and momentum.
Heading into the remainder of fiscal 2026, several factors will shape Emerson's trajectory. The company's next earnings release, expected in mid-November 2026, will be closely watched for confirmation that its raised guidance is on track and that the second-half sales acceleration management has described is materializing. Software annual contract value growth and Test & Measurement order momentum will be key indicators of the higher-margin software shift.
Investors should also monitor the pace of power and semiconductor investment, which have been the primary growth engines, as well as any improvement or further deterioration in Europe and China, where demand has remained soft. Macroeconomic risks such as tariffs, currency movements, and the impact of geopolitical tensions in the Middle East on energy project timing remain relevant headwinds. Competitive pressure in industrial software and AI-driven optimization is intensifying, and the ability to demonstrate tangible customer savings will determine how much of that spending Emerson captures. The company's pivot toward buybacks and dividends also signals a more shareholder-focused capital allocation approach that will be evaluated alongside its organic growth outlook.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EMR saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 60 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 66%.
Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 219 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 151 of 274 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
The 10-day RSI Indicator for EMR moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 19 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 45%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 60 cases where EMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for EMR turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 27 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
EMR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.444) is normal, around the industry mean (3.805). P/E Ratio (35.370) is within average values for comparable stocks, (36.482). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.014) settles around the average of (0.032) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (186.943).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of process controls systems, valves and analytical instruments
Industry IndustrialMachinery